Showing 5291-5300 of 5644 results for "".
- Zeiss Launches First Dual-Speed Swept-Source OCT/OCTA at ARVOhttps://modernod.com/news/zeiss-launches-first-dual-speed-swept-source-oct-octa-at-arvo/2476503/Zeiss launched the PLEX Elite 2.0, the first dual-speed swept-source OCT/OCTA that will scan at 200kHz, in addition to 100kHz, providing doctors a more detailed view into the retina. Varying speeds can be applied to different disease states in the eye and expand re
- Presbia Abandons Flexivue Microlens, Lays Off All But 3https://modernod.com/news/presbia-abandons-flexivue-microlens-lays-off-all-but-3/2476501/Presbia said it spiked its Flexivue microlens development program in the face of FDA headwinds, laying off all but three of its employees as it seeks investors to bail it out, according to a Mass Device report. Earlier this month, the Irvine, Calif.-based company
- Aerie Pharmaceuticals Announces Acceptance of Its IND Application for Sustained-Release Implant for Retinal Diseaseshttps://modernod.com/news/aerie-pharmaceuticals-announces-acceptance-of-its-ind-application-for-sustained-release-implant-for-retinal-diseases/2476498/Aerie Pharmaceuticals announced that the FDA has reviewed the investigational new drug (IND) application for AR-13503, a novel multi-kinase (Rho kinase/Protein kinase C (ROCK/PKC)) inhibitor sustained-release implant, and it is now in effect, allowing Aerie to initiate human studies in the treat
- Oxurion Announces Full Enrollment in its Phase 1 Trial Evaluating the Safety of its Plasma Kallikrein Inhibitor THR-149 for Treatment of DMEhttps://modernod.com/news/oxurion-announces-full-enrollment-in-its-phase-1-trial-evaluating-the-safety-of-its-plasma-kallikrein-inhibitor-thr-149-for-treatment-of-dme/2476492/Oxurion NV announced that it has completed enrollment of its phase 1 study of THR-149, a novel plasma kallikrein (PKal) inhibitor for the treatment of diabetic macular edema (DME). A total of 15 patients have been recruited. The study enrolled faster than anticipated and initial data will be rele
- ProtoKinetix AAGP in Phase 3 Retinal Replacement Programhttps://modernod.com/news/protokinetix-aagp-in-phase-3-retinal-replacement-program/2476493/ProtoKinetix updated its stockholders regarding phase 3 of testing using AAGP in retinal cell replacement therapy at the University of British Columbia. The study is now using 2 animal models and a significantly larger number of animals in both control and AAGP treated groups for a longer
- First Clinical Program Initiated Using Nanoparticles to Treat Retinitis Pigmentosahttps://modernod.com/news/first-clinical-program-initiated-using-nanoparticles-to-treat-retinitis-pigmentosa/2476490/2Ctech announced the initiation of the first-known clinical program to demonstrate the effectiveness and safety of Quantum Dots (QDs) to achieve photovoltaic stimulation of the neural retina for preservation or enhancement of vision in patients with retinal degenerative diseases and, in particula
- Ivantis Announces Publication of Comparative MIGS Clinical Trial Resultshttps://modernod.com/news/ivantis-announces-publication-of-comparative-migs-clinical-trial-results/2476486/Ivantis, developer of the Hydrus Microstent, announced that the 12-month results of the COMPARE study for minimally invasive glaucoma surgery (MIGS) were accepted into the journal Ophthalmology, according to a company news release. COMPARE is the first prospective, multicenter, ra
- Bausch + Lomb Announces New Divisional Leadership in the UShttps://modernod.com/news/bausch-lomb-announces-new-divisional-leadership-in-the-us/2476487/Bausch + Lomb announced the appointment of new leadership in its Pharmaceuticals and Consumer Health Care divisions in the United States. Yolande Barnard, formerly the vice president, marketing and sales, U.S. Neurology, Bausch Health, will now serve as vice president and general manager,
- Innovent Announces First Patient Dosed in a Phase 1 Clinical Trial of IBI302 for the Treatment of Wet AMDhttps://modernod.com/news/innovent-announces-first-patient-dosed-in-a-phase-1-clinical-trial-of-ibi302-for-the-treatment-of-wet-amd/2476478/Innovent Biologics announced that the first patient has been successfully dosed in a phase 1 clinical trial of IBI302, a novel recombinant fully human bispecific fusion protein targeting both vascular endothelium growth factor (VEGF) and complement proteins, for the treatment of wet age-related m
- Texas Tech Medical School to End Use of Race in Admissionshttps://modernod.com/news/texas-tech-medical-school-to-end-use-of-race-in-admissions/2476462/Texas Tech University’s medical school has agreed to end its consideration of race in selecting candidates for admission, an outcome actively sought by the Trump administration. The Texas Tech University Health Sciences Center submitted to pressure from the Education Department’s Offi